FDA Under Fire: Watchdog Exposes 13-Year Delay on Advisory Panel Conflict-of-Interest Rules

A critical government watchdog has exposed a major transparency failure at the U.S. Food and Drug Administration, revealing the agency has operated for over a decade without finalized rules for managing financial conflicts of interest among its powerful advisory committee members. The U.S. Government Accountability Office found the FDA has never completed required guidance mandated by law 13 years ago, leaving a significant gap in public accountability for how these influential panels are staffed.

The GAO review details a pattern of opacity. The agency does not publicly share its decision-making process for determining whether committee members have disqualifying financial ties to the drug or device companies under review. Furthermore, the FDA fails to post on its website how it assesses conflicts for guest speakers invited to these meetings, or how it handles situations where there is an appearance of a conflict, even if a formal one is not found. This lack of a clear, public framework means key decisions about who shapes drug and device approvals occur behind closed doors.

In response, the GAO has issued formal recommendations urging the FDA to establish a concrete timeline for finally issuing and publicly sharing the long-overdue conflict-of-interest guidance. The watchdog also pressed the agency to immediately begin disclosing its interim process for vetting committee members and to make public its methodology for evaluating guest speakers. This pressure places the FDA under heightened scrutiny to reform its practices and restore trust in the integrity of its advisory panels, which play a pivotal role in American public health.